Bakkenolide-IIIa Protects Against Cerebral Damage Via Inhibiting NF-κB Activation
Overview
Pharmacology
Affiliations
Aims: This study was designed to examine the neuroprotective effects of bakkenolide-IIIa, a major novel compound extracted from the rhizome of P. trichinous.
Methods: Transient focal cerebral damage model in rats and oxygen-glucose deprivation (OGD) in cultured hippocampal neurons were performed. The amount of apoptotic neurons was determined using TUNEL assay. The expressions of Bcl-2, Bax, Akt, ERK1/2, IKKβ, IκBα were measured using Western blot. The nuclear translocation and activation of NF-κB was measured using a fluorescence microscope and electrophoretic mobility shift assay (EMSA).
Results: Bakkenolide-IIIa (4, 8, 16 mg/kg; i.g.) was administered immediately after reperfusion could reduce the brain infarct volume, and the neurological deficit, as well as a high dose of bakkenolide-IIIa, increases the 72 h survival rate in cerebrally damaged rats. In vitro data demonstrated that bakkenolide-IIIa could increase cell viability and decrease the amount of apoptotic cells in cultured primary hippocampal neurons exposed to OGD. Bakkenolide-IIIa also dose-dependently increased the ratio of Bcl-2 to Bax. These results indicated that inhibition of apoptosis partly mediated the neuroprotection of bakkenolide-IIIa. Furthermore, bakkenolide-IIIa inhibited the phosphorylation of Akt, ERK1/2, IKKβ, IκBα, and p65 in cultured hippocampal neurons exposed to OGD. Bakkenolide-IIIa not only inhibited the nuclear translocation of NF-κB in cultured neurons exposed to OGD, but also inhibited the activation of NF-κB in peri-infarct area in cerebrally damaged rats.
Conclusion: Collectively, our findings indicated that bakkenolide-IIIa protects against cerebral damage by inhibiting AKT and ERK1/2 activation and inactivated NF-κB signaling.
Li Y, Jin T, Liu N, Wang J, Qin Z, Yin S J Neuroinflammation. 2023; 20(1):53.
PMID: 36855153 PMC: 9972639. DOI: 10.1186/s12974-023-02739-4.
Xu H, Wang E, Chen F, Xiao J, Wang M Oxid Med Cell Longev. 2021; 2021:6687386.
PMID: 34007405 PMC: 8102108. DOI: 10.1155/2021/6687386.
Xu J, Feng H, Ma L, Tan H, Yan S, Fang C Mol Med Rep. 2021; 23(5).
PMID: 33760129 PMC: 7986008. DOI: 10.3892/mmr.2021.12016.
Fu C, Zheng Y, Zhu J, Chen B, Lin W, Lin K Front Pharmacol. 2021; 11:585898.
PMID: 33390957 PMC: 7774511. DOI: 10.3389/fphar.2020.585898.
Tian R, Wang S J Mol Neurosci. 2019; 67(3):456-466.
PMID: 30726543 DOI: 10.1007/s12031-018-1253-5.